NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo (DRC) in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company stated that site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following staff training in the coming weeks.
The trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC. NanoViricides noted that NV-387, a broad-spectrum antiviral candidate, has also been proposed for evaluation against Ebola virus infections, and the shipment makes the drug locally available should it be utilized in response efforts. The company believes successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola.
This development is significant because MPox, particularly the Clade I strain, has been a persistent health threat in the DRC, with limited treatment options. The World Health Organization has highlighted the need for effective therapies. If NV-387 proves safe and effective, it could fill a critical gap. Moreover, its broad-spectrum potential against other viruses like Ebola underscores its importance for global health security.
NanoViricides is a clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed for respiratory viral infections such as RSV, COVID-19, and influenza, as well as MPox and smallpox. The company also has drug candidates for COVID-19, including NV-CoV-2 and NV-CoV-2-R, which encapsulates remdesivir. However, as with all drug development, there is no assurance that any candidate will show sufficient effectiveness and safety for human clinical trials.
The news of the shipment comes amid ongoing efforts to combat MPox outbreaks in Africa. The DRC has experienced recurrent outbreaks, and the availability of a potential treatment could significantly impact public health outcomes. Investors and stakeholders will be watching the trial's progress closely, as successful results could open doors for NV-387 in other viral indications.
For more details, the full press release is available at https://ibn.fm/CTIZc.
